NCT04493164View on ClinicalTrials.gov

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions

Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Ivosidenib

Given PO

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER